Nivolumab‐induced liver injury with a steroid‐refractory increase in biliary enzymes, in a patient with malignant mesothelioma: An autopsy case report

Arai, Kazumori; Matsuda, Masanori; Nakayasu, Hiromasa; Meguro, Shiori; Kurokami, Takafumi; Kubota, Aki; Iwasaki, Takanori; Kawaguchi, Shinya; Iwashita, Toshihide

doi:10.1002/ccr3.5174

Cited by 2 publications

(1 citation statement)

References 27 publications

(151 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An autopsy revealed steroid-refractory hepatotoxicity following nivolumab immunotherapy for malignant mesothelioma. Elevated biliary enzyme levels and randomly distributed endothelial damage emphasized the challenging management of immunerelated toxicities (121).…”

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

Chemotherapy-Induced Liver Injury: Unveiling Emerging Mechanisms and Exploring Mitigation Strategies

Alkabbani,

Shatat,

Ghazy

et al. 2024

ERU Research Journal

View full text Add to dashboard Cite

In this comprehensive overview of chemotherapy-induced liver injury, various classes of chemotherapeutic agents were reviewed to elucidate the complex cellular events contributing to hepatotoxicity and potential mitigation strategies. Alkylating agents, such as cyclophosphamide and busulfan, exhibited diverse mechanisms, with compounds like fucoidan and pyrroloquinoline quinone demonstrating protective effects through modulation of Nrf2/HO-1 and NF-κB pathways.Methotrexate-induced hepatotoxicity, characterized by oxidative stress and inflammation, highlighted the importance of addressing disruptions in lipid metabolism and the gut-liver axis.The multifaceted nature of cisplatin-induced liver damage emphasized the role of gastrointestinal microbiota and therapeutic interventions like curcumin. Anthracyclines, including doxorubicin and epirubicin, posed challenges in mitigating severe hepatotoxicity, with potential protective agents identified. Topoisomerase inhibitors, plant alkaloids, and antitumor antibodies showcased diverse impacts on liver function, emphasizing the need for tailored interventions. Targeted therapies, immune checkpoint inhibitors, and miscellaneous agents like L-asparaginase revealed distinct patterns of hepatotoxicity, prompting a nuanced understanding of patient safety. This comprehensive exploration offers a foundation for future research and therapeutic developments to enhance patient outcomes during chemotherapy.

show abstract

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%